Tuesday November 24 2009 | Biotechnology feed | All feeds
|
|
|
Reportlinker Adds Molecular Diagnostics: A Dynamic and Rapidly Broadening MarketThursday 29th of October 2009 13:51-- Major trends in the molecular diagnostics market, such as the increasing number of tests that are commercially availableChapter 1 BACKGROUND AND SCOPE 1.1. Background 1.2. Focus of This Report Chapter 2 CURRENT AND EMERGING TECHNOLOGIES 2.1. Nonamplified Probe-Based Assays 2.2. Cytogenetics and Fluorescent In Situ Hybridization (FISH) 2.3. Polymerase Chain Reaction (PCR) and Other Amplification Technologies 2.4. Microarrays and Other Multiplex Technologies 2.5. DNA Methylation Assays Epigenomics OncoMethylome Sciences Orion Genomics Rubicon Genomics 2.6. Other Current and Emerging Technologies Chapter 3 CURRENT AND EMERGING APPLICATIONS OF MOLECULAR DIAGNOSTICS: MOVING BEYOND INFECTIOUS DISEASE TESTING 3.1. Oncology: Diagnostic, Prognostic, and Personalized Medicine Tests Testing for HER2/neu Overexpression in Breast Cancer Testing for Epidermal Growth Factor Receptor Analysis of the Expression of Multiple Genes for Breast Cancer Prognosis and Treatment Decisions: Current and Emerging Tests Agendia bioTheranostics Genomic Health Ipsogen Tests in Development for Prediction of Breast Cancer Metastases Analysis of the Expression of Multiple Genes for Other Cancer Applications: Current and Emerging Tests Agendia bioTheranostics Genomic Health Pathwork Diagnostics Analysis of Lymph Nodes to Detect Metastasis of Breast Cancer Other Molecular Tests for Breast Cancer Abbott Molecular AdnaGen Celera ExonHit Therapeutics and bioMerieux Screening for Colorectal Cancer: Stool-Based DNA Screening Exact Sciences OncoMethylome Sciences NorDiag Colorectal Cancer and K-RAS Mutations DxS Qiagen Other Molecular Tests for Colorectal Cancer AdnaGen DiagnoCure Epigenomics ExonHit Therapeutics and bioMérieux OncoMethylome Sciences Molecular Tests for Prostate Cancer AdnaGen CombiMatrix Epigenomics ExonHit Therapeutics and bioMerieux Gen-Probe Leukemias and Lymphomas Abbott Molecular Asuragen Cepheid CombiMatrix InVivoScribe Technologies Roche Molecular Diagnostics Selected Other Companies with Molecular Tests for Leukemia and Lymphoma Outside the United States UGT1A1 Genetic Variants Third Wave Technologies AutoGenomics DNA Methylation Tests and Cancer Epigenomics OncoMethylome Sciences Orion Genomics Rubicon Genomics Human Papillomavirus and Cervical Cancer Screening Other Current and Emerging Molecular Tests for Oncology Abbott Molecular Asuragen Dako DxS Myriad Genetics Roche Molecular Diagnostics 3.2. Personalized Medicine; Pharmacogenomics and Companion Diagnostics: Moving Beyond Oncology Cytochrome P450 and Drug Metabolism Pharmacogenomic Test for Warfarin Response Thiopurine Methyltransferase and Metabolism of Thiopurine Drugs Pharmacogenetics and Response to Antiretroviral Therapy (Anti-HIV Therapy) Other Molecular Diagnostics Personalized Medicine Tests AutoGenomics PGx Health (Part of Clinical Data) XDx 3.3. Genetic Testing: For Inherited Disorders and Prenatal Diagnostics Cystic Fibrosis Prenatal Diagnosis Abbott Molecular CombiMatrix Sequenom Signature Genomic Laboratories Tepnel Ashkenazi Jewish Genetic Panel Comparative Genomic Hybridization Microarrays Other Current and Emerging Molecular Tests for Inherited Disorders 3.4. Genetic Testing: Predicting Risk of Disease Risk of Venous Thromboembolism Predicting Risk of Developing Cancer Myriad Genetics deCODE Genetics Risk of Developing Alzheimer's Disease Athena Diagnostics Innogenetics Celera Risk of Cardiovascular Diseases Celera deCODE Genetics Other Emerging Molecular Tests for Predicting Risk of Disease Celera CombiMatrix deCODE Genetics 3.5. Tables Chapter 4 BUSINESS CONSIDERATIONS IN MOLECULAR DIAGNOSTICS 4.1. Molecular Diagnostics Market Overview 4.2. Major Trends in the Molecular Diagnostics Market Automation, Ease of Use Moving Selected Molecular Diagnostic Tests Nearer to the Patient Growth in Number of New Biomarkers Increasing Efforts on Clinical Validation of Tests Increasing Number of Tests Commercially Available Launching New Tests Through CLIA-Certified Laboratories Impact of FDA Regulations Growing Number of FDA-Cleared and Approved Tests Consolidation (Acquisitions) Competition Increasing Role of Personalized Medicine 4.3. Personalized Medicine and Molecular Diagnostics Treatment of Infectious Diseases Companion Diagnostics and Targeted Therapies Other Personalized Medicine Tests 4.4. Major Challenges Facing Molecular Diagnostic Companies Challenges Associated with Personalized Medicine Market Segment Regulatory Issues and Considerations Regulatory Issues and Considerations for Molecular Diagnostics Clinical Laboratories Regulatory Issues and Considerations for Molecular Diagnostic Companies Regulatory Issues and Consideration for Pharmaceutical Companies Developing Pharmacogenomic Therapies Reimbursement of Molecular Diagnostics Patient and Physician Education Identification of New Biomarkers; Validation of Biomarkers and Diagnostic Tests Chapter 5 EXPERT INTERVIEWS Jeremy Bridge-Cook, PhD, Vice President, Luminex Molecular Diagnostics, Luminex Corporation, Austin, TX David Craford, Vice President, Commercial Operations, Pathwork Diagnostics, Sunnyvale, CA Amit Kumar, PhD, CEO and President, CombiMatrix Corporation, Mukilteo, WA Fareed Kureshy, Founder, Chairman, President, and CEO, AutoGenomics, Carlsbad, CA Jeffrey E. Miller, PhD, CSO, CEO, and Chairman, InVivoScribe Board of Directors, InVivoScribe Technologies, San Diego, CA Mansoor Mohammed, PhD, President and CEO, CombiMatrix Molecular Diagnostics (CMDX) (subsidiary of CombiMatrix Corporation), Irvine, CA Oliver Schacht, PhD, CFO and CEO, Epigenomics Inc., Epigenomics AG, Berlin, Germany John C. Schafer, President and CEO, DiagnoCure, Quebec, Canada James White, CEO, Osmetech plc, Pasadena, CA Matt Winkler, PhD, CEO and CSO, Asuragen, Austin, TX References Company Index with Web Addresses To order this report: Molecular Diagnostics: A Dynamic and Rapidly Broadening Market http://www.reportlinker.com/p0156566/Molecular-Diagnostics-A-Dynamic-and-Rapidly-Broadening-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire More market research reports here!
Contact
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker Browse other news from this organisation: Reportlinker Source PR Newswire  |
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
